Building on Edinburgh’s Translational Platform (BOETP)

Lead Research Organisation: University of Edinburgh

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding.  It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
 
Description British Heart Foundation (SIMLR CIC5)
Amount £300,000 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description CSO grant (CSF1-FC CIC5)
Amount £26,955 (GBP)
Organisation Chief Scientist Office 
Sector Public
Country United Kingdom
Start 04/2019 
End 09/2019
 
Description Developmental Pathway Funding Scheme
Amount £2,000,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start  
 
Description Enterprise Fellowship
Amount £80,000 (GBP)
Organisation Royal Academy of Engineering 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2020 
End 12/2024
 
Description Galecto - Anti-Galectin
Amount £54,256 (GBP)
Organisation Galecto Biotech 
Sector Private
Country Sweden
Start 01/2018 
End 06/2018
 
Description Galecto continued funding for postdoc: IDF project
Amount £35,000 (GBP)
Organisation Galecto Biotech 
Sector Private
Country Sweden
Start 09/2018 
End 12/2018
 
Description Institutional Strategy Support Fund 3: CSF1-FC
Amount £29,281 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2019 
End 12/2019
 
Description MRC DPFS (ENPP6 CIC5)
Amount £124,977 (GBP)
Funding ID MR/R02300X/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 03/2019 
End 03/2020
 
Description Manipulating microglial/macrophage function via CSF-1R to improve functional recovery and neuroplasticity after stroke
Amount £277,547 (GBP)
Organisation Brain Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2020 
End 02/2023
 
Description Medical Research Council CIC (ENPP6 CIC5)
Amount £95,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 07/2017 
End 12/2017
 
Description Newton Mobility Grant (PFK1)
Amount £11,000 (GBP)
Organisation Royal Society of Medicine 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2018 
End 08/2020
 
Description RSE Fellowship (Chicken bioreactor CIC5)
Amount £60,000 (GBP)
Organisation Royal Society of Edinburgh (RSE) 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2017 
End 03/2018
 
Description Selcia - PFK1 CiC5
Amount £120,000 (GBP)
Organisation Selcia 
Sector Private
Country United Kingdom
Start  
 
Description UCB: (IPF)
Amount £89,000 (GBP)
Organisation UCB Pharma 
Sector Private
Country United Kingdom
Start 02/2018 
End 01/2019
 
Description WT-iTPA (Baker)
Amount £19,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 11/2019 
End 11/2020
 
Description iCURE Programme
Amount £35,000 (GBP)
Organisation SETsquared Partnership 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Title Knock down fly lines 
Description Generation of SFXN3 over-expression and SFXN3 knock-down fly lines 
Type Of Material Cell line 
Year Produced 2018 
Provided To Others? No  
Impact Impact unknown 
 
Title Knockout mice 
Description Establishment (through the International Mouse Phenotyping Consortium; IMPC) and characterisation of SFXN3 knockout mice, including aged populations of animals 
Type Of Material Model of mechanisms or symptoms - mammalian in vivo 
Year Produced 2018 
Provided To Others? Yes  
Impact unknown impact 
 
Title Novel Parkinson's disease fly lines (Gillingwater) 
Description Establishment of novel Parkinson's disease fly lines in Edinburgh 
Type Of Material Cell line 
Year Produced 2018 
Provided To Others? No  
Impact Impact unknown 
 
Title New Proteomics database 
Description Extensive new proteomics databases of molecular changes occurring downstream of SFXN3 in the nervous system 
Type Of Material Data analysis technique 
Year Produced 2018 
Provided To Others? No  
Impact unknown impact to date 
 
Description Alfacyte - Chicken bioreactor CIC5 
Organisation Alfacyte Ltd
Country United Kingdom 
Sector Private 
PI Contribution Project plan / IP
Collaborator Contribution Company agreed to put their sequences into PGCs during the course of the project.
Impact No outputs - project in early stages.
Start Year 2017
 
Description Complutense University of Madrid (McColl) 
Organisation Complutense University of Madrid
Country Spain 
Sector Academic/University 
PI Contribution Moro lab, Complutense University of Madrid - collaboration initiated prior to CiC project and PhD visiting PhD student from Moro lab contributed to collection of initial data. MTA/CDA signed with Madrid to enable sharing of data and tissue samples. Collaboration is ongoing and contributed to award of a Fondation Leducq grant
Collaborator Contribution Moro lab, Complutense University of Madrid - collaboration initiated prior to CiC project and PhD visiting PhD student from Moro lab contributed to collection of initial data. MTA/CDA signed with Madrid to enable sharing of data and tissue samples. Collaboration is ongoing and contributed to award of a Fondation Leducq grant
Impact Contributed to grant award
Start Year 2017
 
Description Elasmogen - Chicken bioreactor 
Organisation Elasmogen Ltd
Country United Kingdom 
Sector Private 
PI Contribution Project idea / IP
Collaborator Contribution Company putting their sequences into PGCs during course of project.
Impact No outcomes - project in early stages.
Start Year 2017
 
Description Galecto - Anti-galectin CIC5 
Organisation Galecto Biotech
Country Sweden 
Sector Private 
PI Contribution Project / academic IP
Collaborator Contribution Pipeline
Impact Project in early stages so outcome will be reported next year.
Start Year 2017
 
Description Galecto BioTech further funding 
Organisation Galecto Biotech
Country Sweden 
Sector Private 
PI Contribution underpinning science for project provided by UoE academics
Collaborator Contribution Galecto - providing expertise, joint submission on funding applications and financial contribution to staff / research. Discussion re spinout underway between University and Galecto
Impact no outputs to date. Spin out under discussion
Start Year 2018
 
Description Moon Lab at Kings College London 
Organisation King's College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Moon lab, King's College London - initiated on back of data generated in CiC project to develop project proposal for assessing longer-term effects of CSF1-Fc using a stroke model and behavioural outcomes used by the Moon lab. Has enabled a grant application to Brain Research UK
Collaborator Contribution Moon lab, King's College London - initiated on back of data generated in CiC project to develop project proposal for assessing longer-term effects of CSF1-Fc using a stroke model and behavioural outcomes used by the Moon lab. Has enabled a grant application to Brain Research UK
Impact No outputs to date
Start Year 2019
 
Description Novartis (CSF1-FC CIC5_ 
Organisation Novartis
Country Global 
Sector Private 
PI Contribution Novartis currently hold an exclusive option to a license for human indications to exploit CSF1-Fc as defined in PCT/GB2014/050595. Novartis indicated support for further regenerative medicine applications during CiC proposal submission
Collaborator Contribution Novartis indicated support for further regenerative medicine applications during CiC proposal submission
Impact No outputs to report to date
Start Year 2017
 
Description UCB partnership (Anti Galectin CIC5) 
Organisation UCB Pharma
Country United Kingdom 
Sector Private 
PI Contribution Discovery research
Collaborator Contribution Expertise
Impact Current partnership - no outcomes to report to date
Start Year 2018
 
Description University of Glasgow (Gillingwater) 
Organisation University of Glasgow
Country United Kingdom 
Sector Academic/University 
PI Contribution Underpinning science of project
Collaborator Contribution UoG provided world leading mitochondrial expertise which means project is better placed to explore the molecular mechanisms through which SFXN3 regulates neurodegeneration
Impact Collaboration will progress project and aid further funding
Start Year 2018
 
Title A READING SYSTEM, TEXT DISPLAY METHOD AND APPARATUS 
Description A reading system comprises an apparatus comprising a screen and a processor configured to display a sequence of text to a reader in a reading process; and at least one processing resource configured to obtain reading data representative of at least one property of the text and/or the reading process, and to process the reading data to identify changes in the reading data over time that may be indicative of visual or neurological deterioration and/or the presence of at least one condition in the reader. 
IP Reference WO2018046957 
Protection Patent granted
Year Protection Granted 2018
Licensed No
Impact No impact to date.
 
Title MACROPHAGE-BASED THERAPY FOR USE IN THE TREATMENT OF LIVER INJURY 
Description The present invention relates to alternatively activated macrophages (AAMs) for use in the treatment of liver injury and methods of treating and preventing liver injury using AAMs. 
IP Reference WO2018051136 
Protection Patent application published
Year Protection Granted 2018
Licensed Yes
Impact Significant funding from one tier UK investor
 
Title MATERIALS AND METHODS FOR THE TREATMENT OF VASCULAR DISEASE 
Description The invention provides a method of treating a vascular condition within a subject comprising administering a therapeutic agent to said subject that is capable of modulating the expression levels of a long non-coding RNA (IncRNA) selected from the group consisting of lncRNA2, lncRNA4, lncRNA5, lncRNA6, ncRNA7 and ncRNA8 as defined in figure 39. 
IP Reference WO2016146996 
Protection Patent application published
Year Protection Granted 2016
Licensed No
Impact No impact to date
 
Description Anatomy@Edinburgh public engagement programme 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Schools
Results and Impact Both Professor Gillingwater and Dr Wishart have engaged in extensive public engagement activities over the duration of the CiC award, during which we were able to communicate our work concerning neurodegeneration to a range of diverse audiences. Many of these activities were coordinated through the Anatomy@Edinburgh public engagement programme (including visits to, and from, primary and secondary school children). Further details can be found at: https://www.ed.ac.uk/biomedical-sciences/anatomy
Year(s) Of Engagement Activity 2018
URL https://www.ed.ac.uk/biomedical-sciences/anatomy
 
Description Research and combined patient group meetings 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Both applicants have been invited to chair sessions and present research at several combined research/patient group meetings for Neuronal Ceroid Lipofuscinoses (Batten Disease) and spinal muscular atrophy (SMA).
Year(s) Of Engagement Activity 2018